A multicenter, non-interventional observational study to evaluate 1-year clinical outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) and Prasugrel therapy.
Latest Information Update: 13 Nov 2019
At a glance
- Drugs Prasugrel (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms EFF-K study
- Sponsors Daiichi Sankyo Korea
- 23 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2017 New trial record